{"id":"e9351586-a1cb-5fdd-8685-2f21fbbf032c","stable_key":"3238e4f0-8d45-5c72-8624-6e9a8b20527c:ibu-slow-clearance-more-effect","predicate":"reduces","statement":"Population mean S-ibuprofen clearances were 3.25, 2.38 and 1.52 litres per hour in carriers of CYP2C9 genotypes *1/*1, *1/*3 and *3/*3 respectively while the *2 variant had no significant effect, and ex vivo formation of thromboxane B2 reflecting cyclooxygenase-1 inhibition depended significantly on the polymorphism, with maximal inhibition and the area under the effect-time curve larger in carriers of the slow genotypes, the same trend holding for prostaglandin E2.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"cc4aa30b-34c1-5e1b-b5f2-a62c91005273","mechanism_event_label":"People who clear the active half slowly get both more drug and more effect from the same tablet.","subject":{"id":"20d9d560-e791-5842-96fc-bb13bfd866fc","slug":"cyp2c9-ile359leu","display_name":"The CYP2C9 isoleucine 359 leucine variant, CYP2C9*3","entity_type_key":"protein_state"},"object":{"id":"04282f17-56c4-54a9-aa33-37bc4c537c87","slug":"s-ibuprofen","display_name":"S(+)-ibuprofen","entity_type_key":"small_molecule"},"evidence_count":1,"mechanism_event":{"id":"cc4aa30b-34c1-5e1b-b5f2-a62c91005273","stable_key":"3238e4f0-8d45-5c72-8624-6e9a8b20527c:ibu-slow-clearance-more-effect-event","event_type":"observed_intervention","label":"People who clear the active half slowly get both more drug and more effect from the same tablet.","description":"Population mean S-ibuprofen clearances were 3.25, 2.38 and 1.52 litres per hour in carriers of CYP2C9 genotypes *1/*1, *1/*3 and *3/*3 respectively while the *2 variant had no significant effect, and ex vivo formation of thromboxane B2 reflecting cyclooxygenase-1 inhibition depended significantly on the polymorphism, with maximal inhibition and the area under the effect-time curve larger in carriers of the slow genotypes, the same trend holding for prostaglandin E2.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"c96f78f4-5bca-5867-9ac1-652891d40aa0","slug":"cyp2c9","display_name":"Human cytochrome P450 2C9","entity_type_key":"protein"},"role":"affected_enzyme","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"3b200ef2-893f-5ca7-93f4-ea657577a760","slug":"thromboxane-b2","display_name":"Thromboxane B2","entity_type_key":"small_molecule"},"role":"measured_readout","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"5733d7d1-6259-588f-a4a9-4d0dc0133735","slug":"prostaglandin-e2","display_name":"Prostaglandin E2","entity_type_key":"small_molecule"},"role":"co_measured","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"20d9d560-e791-5842-96fc-bb13bfd866fc","slug":"cyp2c9-ile359leu","display_name":"The CYP2C9 isoleucine 359 leucine variant, CYP2C9*3","entity_type_key":"protein_state"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"04282f17-56c4-54a9-aa33-37bc4c537c87","slug":"s-ibuprofen","display_name":"S(+)-ibuprofen","entity_type_key":"small_molecule"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/ibuprofen-research/12152005.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"314477c44dbb699b0fe3d9ab14eb7da427d88538177b4e4267ef0ad25fd407da\", \"start_char\": 0, \"end_char\": 1822, \"text_sha256\": \"314477c44dbb699b0fe3d9ab14eb7da427d88538177b4e4267ef0ad25fd407da\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Population pharmacokinetic study in 21 healthy volunteers across all combinations of CYP2C9 variants","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"600 milligrams oral racemic ibuprofen, with thromboxane B2 and prostaglandin E2 measured ex vivo","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Links a genotype to both the drug level and the enzyme effect in the same subjects. Twenty-one volunteers spread across genotype groups, so each group is small.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Ibuprofen research collection; topical membership is not evidence of a direct clinical effect, and the racemate is recorded separately from each of its two enantiomers.","comparator":null,"unit":null,"notes":"","entity":{"slug":"ibuprofen","display_name":"Ibuprofen","entity_type_key":"drug"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"People who clear the active half slowly get both more drug and more effect from the same tablet.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[ibu-p12152005] Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. (2002). https://pubmed.ncbi.nlm.nih.gov/12152005/ DOI: 10.1067/mcp.2002.125726","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Plasma, platelets and monocytes","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"a4d6bfb5-b40d-506e-814b-4df4e11e2626","evidence_kind":"source_excerpt","locator":"Lines 214-225","start_line":214,"end_line":225,"excerpt":"### ibu-slow-clearance-more-effect\nPopulation mean S-ibuprofen clearances were 3.25, 2.38 and 1.52 litres per hour in carriers of CYP2C9 genotypes *1/*1, *1/*3 and *3/*3 respectively while the *2 variant had no significant effect, and ex vivo formation of thromboxane B2 reflecting cyclooxygenase-1 inhibition depended significantly on the polymorphism, with maximal inhibition and the area under the effect-time curve larger in carriers of the slow genotypes, the same trend holding for prostaglandin E2.\nCondition category: machinery_impairment\nnutrient_topic: Ibuprofen research collection; topical membership is not evidence of a direct clinical effect, and the racemate is recorded separately from each of its two enantiomers.\nplain_language: People who clear the active half slowly get both more drug and more effect from the same tablet.\norganism: Human\ntissue_or_cell_type: Plasma, platelets and monocytes\nexperimental_model: Population pharmacokinetic study in 21 healthy volunteers across all combinations of CYP2C9 variants\nlimitations: Links a genotype to both the drug level and the enzyme effect in the same subjects. Twenty-one volunteers spread across genotype groups, so each group is small.\nexposure: 600 milligrams oral racemic ibuprofen, with thromboxane B2 and prostaglandin E2 measured ex vivo\nevidence_span: {\"source_cache\": \"artifacts/ibuprofen-research/12152005.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"314477c44dbb699b0fe3d9ab14eb7da427d88538177b4e4267ef0ad25fd407da\", \"start_char\": 0, \"end_char\": 1822, \"text_sha256\": \"314477c44dbb699b0fe3d9ab14eb7da427d88538177b4e4267ef0ad25fd407da\"}\n[ibu-p12152005] Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. (2002). https://pubmed.ncbi.nlm.nih.gov/12152005/ DOI: 10.1067/mcp.2002.125726","model_system":"Population pharmacokinetic study in 21 healthy volunteers across all combinations of CYP2C9 variants","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [ibu-p12152005] Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. (2002). https://pubmed.ncbi.nlm.nih.gov/12152005/ DOI: 10.1067/mcp.2002.125726","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"31c4939d-f520-55c0-973b-224743caf245","stable_key":"import-3238e4f0-8d45-5c72-8624-6e9a8b20527c","title":"Ibuprofen: the enantiomer that works, the one that was called inactive, the one-way chemistry that turns one into the other, and the targets that are not cyclooxygenase (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"cc2b388178f97f5906b66ecbe441fc5c86d51fd645947c5260fb0b4bdb4bcd21","revision_id":"0b4e5c65-05d3-5430-a4cd-8d6a03647dcb","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}